Arcturus Therapeutics Holdings Inc.

01/25/2022 | Press release | Distributed by Public on 01/25/2022 07:11

Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial